Check out Guardant Health Inc.’s new product website at guardant360cdx.com. Find out how our test can help treat at the speed of cancer. Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling of patients across all solid cancers, providing doctors with complete genomic results in 7 days from sample receipt in the laboratory to inform first-line treatment plans fast.

If you are a medical oncologist in Asia, Middle East or Africa, visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at [email protected] or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.